Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking LAIR-collagen interaction
M. I. P. Ramos, L. Tian, E. J. de Ruiter, C. Song, A. Paucarmayta, A. Singh, E. Elshof, S. V. Vijver, J. Shaik, J. Bosiacki, Z. Cusumano, L. Liu, S. Langermann, S. Willems, D. Flies, L. Meyaard
Abstract
Collagens are a primary component of the extracellular matrix and are functional ligands for the inhibitory immune receptor leukocyte associated immunoglobulin-like receptor-1 (LAIR-1). Leukocyte associated immunoglobulin-like receptor-2 (LAIR-2) is a secreted protein that can act as a decoy receptor by binding collagen with higher affinity than LAIR-1. We propose that collagens promote immune evasion by interacting with LAIR-1 and that LAIR-2 could release LAIR-1 mediated immune suppression. Analysis of public datasets shows high LAIR-2 expression being associated with a favorable outcome in certain tumors. We designed a dimeric LAIR-2 with a functional IgG1 Fc tail, NC410, and showed that NC410 reduces tumor growth and increases T cell expansion and effector function in humanized tumor models. Immunohistochemical analysis of human tumors shows that NC410 binds to collagen-rich areas where LAIR-1+ immune cells are localized. Our findings show that NC410 might be a powerful new strategy for cancer immunotherapy for immune-excluded tumors.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Collagen remodeling promotes a GPCR-mediated mechanosensory immune checkpoint in ADGRG1+ CD8+ T cells and serves as a spatial biomarker of response to immunotherapy
Sonal Srivastava, John Joseph Powers, … Antonio L. Amelio·bioRxiv·Dec 22, 2025
- CREB5 promotes immunotherapy resistance via tumor-intrinsic collagenmatrix deposition
Payal Tiwari, Kayla J. Colvin, … Robert T. Manguso·bioRxiv·Apr 22, 2025
- Extracellular DDR1 targeting remodels collagen-rich tumor stroma and local immunity
Xuan Huang, Xinlin Liu, … Li Ye·bioRxiv·Nov 3, 2026
- Dual targeting of CCR2+ monocytes and neutrophils enhances anti-tumor immunity
Klaire Yixin Fjæstad, Astrid Zedlitz Johansen, … Daniel Hargbøll Madsen·bioRxiv·May 15, 2026
- Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer Immunotherapy
- The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune check-point inhibitors